BCL2 and plasma cell neoplasm: Previously, the oral B‐cell/CLL lymphoma 2 (BCL2) inhibitor venetoclax has demonstrated promising efficacy in patients with t(11;14) plasma cell disorders, both as a single agent and in combination [12].